Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glabellar Frown Lines Clear all
Completed Phase 3 Interventional Results available

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

NCT03004248
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
QM1114-DP, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Homewood, Alabama • Manhattan Beach, California • Vista, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

The Treatment of Glabellar Frown Lines

NCT02096081
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA, OnabotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

NCT01583478
View directory record Official record
Conditions
Skin Aging, Elastosis Senilis
Interventions
incobotulinumtoxinA
Biological
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 3, 2026, 1:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

NCT01801826
View directory record Official record
Conditions
Frown Lines, Glabellar Frown Lines
Interventions
Treatment with CryoTouch IV
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beverly Hills, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows

NCT00752297
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Preservative-free Saline, Mentor Purified Toxin
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

NCT00512135
View directory record Official record
Conditions
Glabellar Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 units)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Englewood, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

NCT02939326
View directory record Official record
Conditions
Glabellar Frown Lines (GL)
Interventions
EB-001 injection, Placebo injection
Drug
Lead sponsor
Bonti, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Fremont, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01224015
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

NCT02236312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Mobile, Alabama • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

NCT00752258
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Mentor Purified Toxin Botulinum Toxin Type A
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 3, 2026, 1:53 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

NCT05305768
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Encino, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

NCT03786770
View directory record Official record
Conditions
Frown Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boca Raton, Florida • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03736928
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA dose level 1 or 2, placebo, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
10
States / cities
Encino, California • Manhattan Beach, California • Vista, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

NCT03806933
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
NT 201
Drug
Lead sponsor
Merz Aesthetics GmbH
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Encino, California • Newport Beach, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 3, 2026, 1:53 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

NCT05083286
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Encino, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

NCT04259086
View directory record Official record
Conditions
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Interventions
DaxibotulinumtoxinA for injection
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Manhattan Beach, California • San Diego, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

AI-09 In Subjects With Glabellar Lines, GL-101

NCT05565950
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AI-09, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
20 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 3, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 3, 2026, 1:53 PM EDT